Total circulating cell‐free miRNA in plasma as a predictive biomarker of the thyroid diseases

• Published in: Journal of cellular biochemistry 2019-06, Vol.120 (6), p.9016-9022
• Main Authors: Caglar, Ozge, Cayir, Akin
• Format: Article
• Language: English
• Subjects: Benign; Biomarkers; Blood; Body fluids; Cancer; Developmental stages; diagnosis; Diagnostic systems; Diseases; Hashimoto's thyroiditis; Metabolic pathways; miRNA; Molecular modelling; Nodules; Patients; prognosis; Signal transduction; Therapeutic applications; Thyroid; Thyroid cancer; thyroid disease; Thyroid diseases; Thyroiditis; Tumors
• ISSN: 0730-2312; 1097-4644
• DOI: 10.1002/jcb.28173

Background Thyroid cancer is a common endocrine cancer. Great progress has been made in resolving its molecular mechanisms in recent years. The molecular changes observed in thyroid cancer can be used as biomarkers for diagnostic, prognostic and therapeutic purposes. MicroRNAs (miRNAs) are important components in biological and metabolic pathways, such as developmental stages, signal transduction, cell maintenance, and differentiation. Hence, their malfunctioning can expose humans to malignancies. miRNA expressions have been shown to be dysregulated in different tumor types, like thyroid cancer, and may cause tumor initiation and progression. In previous studies, only cancer has been studied, and miRNA has been detected from the tissues in all the studies performed. In this study, we have focused on thyroid diseases such as bening nodules and Hashimoto's disease, which might be the cause of thyroid cancer, and have carried out miRNA tests in the blood samples taken from the arms thyroid patients. Material and method The present study was conducted on the blood samples of 100 thyroid patients. Of the 100 patients in our study, 33 consisted of patients with thyroiditis, while 37 patients were diagnosed with benign thyroid nodules and 30 patients had thyroid cancer. For the control group, 18 patients were included. The plasma samples were analyzed, and the total miRNA levels were determined. Results We found that the ccf‐miRNA amount of benign patients is significantly lower than that of the controls. Similarly, the miRNA amount in the controls is significantly higher than that of the thyroiditis (P = 0.06) and the malign groups miRNA (P = 0.084). Although the present study has a low number of patients, the plasma samples could be used as a source of circulating miRNAs. In addition, the total miRNA of thyroid diseases could be used as a biomarker for different types of thyroid diseases. We could suggest, for future study, that specific miRNAs in bodily fluid might show specific properties to be used as biomarkers of thyroid diseases. The total miRNA of thyroid diseases can be used as a biomarker for diagnosis, prognosis, and follow‐up of patients.